FEATURED AUTHORITIES ON PRECISION ONCOLOGY
Professor of Medicine
Université Claude Bernard
Professor of Experimental Cancer Medicine
Royal Marsden Hospital
Austin Health Cancer Services
Professor of Medical Oncology
Yonsei University College of Medicine
Vall d'Hebron Institute of Oncology
Division of Hematology Oncology
Samsung Medical Center
Director of Precision Medicine
The Angeles Clinic and Research Institute
Clinical Senior Lecturer
The University of Manchester
Chief, Division of Hematology and Oncology
UCSD School of Medicine
Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Professor of Medicine and Medical Oncology
Senior Consultant Medical Oncology
National Cancer Centre Singapore
Specialist in Medical Oncology
The University of Hong Kong
Tenured Associate Professor
University of Texas MD Anderson Cancer Center
Professor, Division of Genomic and Molecular Pathology
University of Chicago Medical Center
Professor, Graduate Institute of Oncology
National Taiwan University
iQ&A interactive Medical Intelligence Zone welcomes your questions and your participation in the iQ&A community.
Why is hybrid capture-based sequencing the optimal molecular profiling platform in the context of precision cancer medicine? And can you use long cancer as an example of how NGS can generate specific drug alignments?
Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy?
What is the value of molecular profiling in the first line setting?
In what spectrum of tumors and at what point in the natural history of the disease do you use NGS-based molecular profiling?
How do the capabilities of NGS compare to hot spot testing, and why is whole exome sequencing based on hot spot panels preferred in the setting of precision oncology practice?
In South Korea, how are you using NGS-based molecular profiling in the setting of NSCLC?
What is the role of NGS-based molecular profiling for providing roadmaps suggesting how combination, targeted therapy can produce improved clinical outcomes?
In your practice, how early do you recommend performing whole exome sequencing and in what types of tumors, and is it critical to detect mutations, translocations, allelic fractions, and amplifications?
From a precision medicine perspective, how should we be integrating and incorporating ctDNA profiling — i.e., liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?
What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other molecular alterations might trigger immunotherapy based on NGS-generated markers and drivers agnostic to tumor type?
What are the implications of FDA approval of PD-1 inhibitors for MSI-high tumors, and what other canonical molecular alterations —NTRK and others — do you see on the horizon that might trigger immunotherapy based on NGS-generated markers ...
Given some of the conflicting results reported by precision medicine trials, how do you reconcile some of the divergent results and their implications for NGS-based molecular stratification?
What are the possible limitations of NGS and what is the importance of working with a molecular tumor board?